


FORM PTO-1449

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.
226/104SERIAL NO.
08/870,762APPLICANT:
Bradford Duft et al.FILING DATE:
June 6, 1997GROUP:
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
SD	AA	5,175,145	12/29/92	Cooper			
SD	AB	5,234,906	8/10/93	Young et al.			RECEIVED
SD	AC	5,364,841	11/15/94	Cooper et al.			JAN 05 1999
SD	AD	5,656,590	8/12/97	Rink et al.			

MAILED 05/05/99
SERVICE CENTER

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SD	AE	Kolterman et al., "Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue," <u>Diabetes Care</u> 18(8):(Abstract) (1995)
SD	AF	Kong et al., "Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM," <u>Diabetologia</u> 40(1):82-88 (1997)
SD	AG	Kong et al., "The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM," <u>Diabetologia</u> 41(5):577-583 (1998)
SD	AH	Nyholm et al., "Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus," <u>J. Clin. Endocrinol. Metab.</u> 81(3):1083-1089 (1996)
SD	AI	Schmitz et al., "Effects of amylin and the amylin agonist pramlintide on glucose metabolism," <u>Diabetic Med.</u> 14(2):S19-S23 (1997)
SD	AJ	Thompson et al., "Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations," <u>Diabetologia</u> 40(11):1278-1285 (1997)
SD	AK	Thompson et al., "Pramlintide: A human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes," <u>Diabetic Med.</u> 14(7):547-555 (1997)

EXAMINER:

SD

DATE CONSIDERED:

21 June 99

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.